Based on current results Probiotec Limited provided earnings guidance for the balance of the half year ended December 31, 2017. For the period, the company to report net profit before tax in the range of $1.0 million to $1.4 million, or an increase of 40% to 100%, compared to the $0.7 million achieved in the prior corresponding period. As advised on November 23, 2017, in the absence of any significant deterioration in economic conditions, the Directors reasonably expect to deliver strong growth in both revenue and earnings in the 2018 financial year. This will be driven most heavily by demand for contract manufacturing services that continue to perform strongly, together with growth in pharmaceutical and obesity management branded portfolio. The recent acquisition of South Pack Laboratories (South Pack) will supplement this growth with a circa nine months contribution to earnings (before transaction costs).